* Atrix Laboratories Inc., of Fort Collins, Colo., received an approvable letter from the FDA for Atridox, a product used in the treatment of periodontal disease. Following a decision on product labeling, Atrix expects FDA marketing approval. In addition, under terms of its North American marketing agreement with Block Drug Corp., in Jersey City, N.J., Atrix received a $7 million milestone payment.
* Introgen Therapeutics Inc., of Austin, Texas, said Oncormed Inc. of Gaithersburg, Md., will conduct p53 testing for Introgen's Phase I trials of its adenoviral p53 gene therapy. The testing will provide analysis of clinical tissue samples to expand the understanding of the p53 tumor suppressor gene's role in cancer.